Ad­comm rec­om­mends FDA re­ject Brain­Stor­m's ALS drug af­ter com­pa­ny filed over protest

A pan­el of in­de­pen­dent ex­perts on Wednes­day rec­om­mend­ed the FDA re­ject an ex­per­i­men­tal ALS drug de­vel­oped by the biotech Brain­Storm Cell Ther­a­peu­tics, mark­ing an­oth­er de­feat for the long-em­bat­tled com­pa­ny.

Mem­bers of the Cel­lu­lar, Tis­sue, and Gene Ther­a­pies Ad­vi­so­ry Com­mit­tee said by a 17-1 vote that Brain­Storm’s drug, known as NurOwn, did not demon­strate sub­stan­tial ev­i­dence of ef­fec­tive­ness for the treat­ment of mild to mod­er­ate ALS. The FDA has un­til Dec. 8 to ap­prove or re­ject the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER